On Tuesday, Verona Pharma Plc ADR (NASDAQ: VRNA) opened higher 0.99% from the last session, before settling in for the closing price of $58.75. Price fluctuations for VRNA have ranged from $11.39 to $62.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -49.71%. Company’s average yearly earnings per share was noted -177.78% at the time writing. With a float of $68.91 million, this company’s outstanding shares have now reached $81.83 million.
The extent of productivity of a business whose workforce counts for 79 workers is very important to gauge. In terms of profitability, gross margin is 80.41%, operating margin of -2370.63%, and the pretax margin is -2352.52%.
Verona Pharma Plc ADR (VRNA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Verona Pharma Plc ADR is 15.79%, while institutional ownership is 68.71%. The most recent insider transaction that took place on Dec 05 ’24, was worth 3,205,226. In this transaction President and CEO of this company sold 640,264 shares at a rate of $5.01, taking the stock ownership to the 14,367,552 shares. Before that another transaction happened on Dec 06 ’24, when Company’s President and CEO sold 162,800 for $5.01, making the entire transaction worth $815,400. This insider now owns 14,204,752 shares in total.
Verona Pharma Plc ADR (VRNA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -177.78% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Check out the current performance indicators for Verona Pharma Plc ADR (VRNA). In the past quarter, the stock posted a quick ratio of 13.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 854.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.94, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.05 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
The latest stats from [Verona Pharma Plc ADR, VRNA] show that its last 5-days average volume of 1.29 million was inferior to 1.54 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 70.06%. Additionally, its Average True Range was 2.59.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 92.25%, which indicates a significant increase from 71.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.61% in the past 14 days, which was lower than the 48.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.14, while its 200-day Moving Average is $30.26. Now, the first resistance to watch is $60.16. This is followed by the second major resistance level at $60.99. The third major resistance level sits at $62.43. If the price goes on to break the first support level at $57.89, it is likely to go to the next support level at $56.45. The third support level lies at $55.62 if the price breaches the second support level.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
There are currently 80,440K shares outstanding in the company with a market cap of 4.85 billion. Presently, the company’s annual sales total 0 K according to its annual income of -54,370 K. Last quarter, the company’s sales amounted to 5,620 K and its income totaled -42,960 K.
